HRP20110919T1 - Nova upotreba alfuzosina u terapiji - Google Patents
Nova upotreba alfuzosina u terapiji Download PDFInfo
- Publication number
- HRP20110919T1 HRP20110919T1 HR20110919T HRP20110919T HRP20110919T1 HR P20110919 T1 HRP20110919 T1 HR P20110919T1 HR 20110919 T HR20110919 T HR 20110919T HR P20110919 T HRP20110919 T HR P20110919T HR P20110919 T1 HRP20110919 T1 HR P20110919T1
- Authority
- HR
- Croatia
- Prior art keywords
- alfuzosin
- alfuzosine
- adrenergic
- therapeutic uses
- novel therapeutic
- Prior art date
Links
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 title claims abstract 7
- 230000001800 adrenalinergic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960004607 alfuzosin Drugs 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 230000002265 prevention Effects 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 229960003103 alfuzosin hydrochloride Drugs 0.000 claims 1
- YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 claims 1
- 206010063057 Cystitis noninfective Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Alfuzosin, ili njegove farmaceutski prihvatljive soli, naznačen time što je namijenjen upotrebi u liječenju i/ili sprječavanju upale mokraćnog mjehura. Patent sadrži još 3 patentna zahtjeva.
Claims (4)
1. Alfuzosin, ili njegove farmaceutski prihvatljive soli, naznačen time što je namijenjen upotrebi u liječenju i/ili sprječavanju upale mokraćnog mjehura.
2. Alfuzosin, ili njegove farmaceutski prihvatljive soli, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedena upala mokraćnog mjehura posljedica ili je povezana s intersticijskim cistitisom.
3. Alfuzosin, ili njegove farmaceutski prihvatljive soli, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što alfuzosin je alfuzosin-hidroklorid.
4. Alfuzosin, ili njegove farmaceutski prihvatljive soli, naznačen time što je namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva kod muških pacijenata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97532407P | 2007-09-26 | 2007-09-26 | |
| EP07291148A EP2042179A1 (en) | 2007-09-26 | 2007-09-26 | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
| PCT/IB2008/003126 WO2009040671A1 (en) | 2007-09-26 | 2008-09-24 | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110919T1 true HRP20110919T1 (hr) | 2012-01-31 |
Family
ID=38754714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110919T HRP20110919T1 (hr) | 2007-09-26 | 2011-12-06 | Nova upotreba alfuzosina u terapiji |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8492396B2 (hr) |
| EP (2) | EP2042179A1 (hr) |
| JP (1) | JP5478495B2 (hr) |
| AR (1) | AR068825A1 (hr) |
| AT (1) | ATE524185T1 (hr) |
| CY (1) | CY1112203T1 (hr) |
| DK (1) | DK2203170T3 (hr) |
| ES (1) | ES2373354T3 (hr) |
| HR (1) | HRP20110919T1 (hr) |
| ME (1) | ME01259B (hr) |
| PL (1) | PL2203170T3 (hr) |
| PT (1) | PT2203170E (hr) |
| RS (1) | RS52069B (hr) |
| SI (1) | SI2203170T1 (hr) |
| WO (1) | WO2009040671A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020015377A1 (zh) * | 2018-07-18 | 2020-01-23 | 温州医科大学 | 一种治疗近视的方法及制备药物的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2582513B1 (fr) * | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
| US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
| ATE327800T1 (de) * | 1997-07-10 | 2006-06-15 | Therakos Inc | Behandlung von darm- oder blasenentzündungen |
| CA2434436A1 (en) * | 2001-01-26 | 2002-08-01 | Teddy Kosoglou | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| WO2002062389A1 (fr) * | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
| CA2440141A1 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| AU2003260373B2 (en) * | 2002-08-14 | 2008-02-21 | Janssen Pharmaceutica N.V. | Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| WO2005005395A2 (en) * | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
| US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
-
2007
- 2007-09-26 EP EP07291148A patent/EP2042179A1/en not_active Withdrawn
-
2008
- 2008-09-24 RS RS20110553A patent/RS52069B/en unknown
- 2008-09-24 AR ARP080104131A patent/AR068825A1/es unknown
- 2008-09-24 JP JP2010526392A patent/JP5478495B2/ja not_active Expired - Fee Related
- 2008-09-24 PL PL08833688T patent/PL2203170T3/pl unknown
- 2008-09-24 DK DK08833688.8T patent/DK2203170T3/da active
- 2008-09-24 ME MEP-2011-204A patent/ME01259B/me unknown
- 2008-09-24 AT AT08833688T patent/ATE524185T1/de active
- 2008-09-24 PT PT08833688T patent/PT2203170E/pt unknown
- 2008-09-24 EP EP08833688A patent/EP2203170B1/en active Active
- 2008-09-24 SI SI200830471T patent/SI2203170T1/sl unknown
- 2008-09-24 ES ES08833688T patent/ES2373354T3/es active Active
- 2008-09-24 WO PCT/IB2008/003126 patent/WO2009040671A1/en active Application Filing
-
2010
- 2010-03-24 US US12/730,559 patent/US8492396B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 HR HR20110919T patent/HRP20110919T1/hr unknown
- 2011-12-14 CY CY20111101243T patent/CY1112203T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009040671A4 (en) | 2009-05-28 |
| JP5478495B2 (ja) | 2014-04-23 |
| US20110009436A1 (en) | 2011-01-13 |
| US8492396B2 (en) | 2013-07-23 |
| SI2203170T1 (sl) | 2012-01-31 |
| ES2373354T3 (es) | 2012-02-02 |
| WO2009040671A1 (en) | 2009-04-02 |
| RS52069B (en) | 2012-06-30 |
| EP2203170B1 (en) | 2011-09-14 |
| ME01259B (me) | 2013-06-20 |
| PL2203170T3 (pl) | 2012-02-29 |
| DK2203170T3 (da) | 2012-01-16 |
| PT2203170E (pt) | 2011-12-27 |
| JP2010540511A (ja) | 2010-12-24 |
| CY1112203T1 (el) | 2015-12-09 |
| EP2042179A1 (en) | 2009-04-01 |
| EP2203170A1 (en) | 2010-07-07 |
| AR068825A1 (es) | 2009-12-09 |
| ATE524185T1 (de) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| DE602007014186D1 (de) | Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer | |
| RS53096B (en) | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | |
| RS54651B1 (en) | JANUS KINAS INHIBITORS for the treatment of dry eye and other eye diseases | |
| EA201000563A1 (ru) | Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
| AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
| NZ602571A (en) | Micrornas that regulate muscle cell proliferation and differentiation | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| NZ601148A (en) | Use of pentosan polysulfate for treatment or prophylaxis of allergic rhinitis | |
| MD3347002T2 (ro) | Tratamentul bolii Alzheimer într-o populație specifică de pacienți | |
| NZ602029A (en) | Use of meloxicam for the long-term treatment of kidney disorders in cats | |
| MY151835A (en) | Kinase inhibitors and methods of use thereof | |
| RU2007122391A (ru) | S-миртазапин для лечения приливов | |
| CO6361995A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
| MX2021008136A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met. | |
| WO2015061777A3 (en) | Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema | |
| DK1580201T3 (da) | Vandig behandlingssammensætning og polymerer til brug heri | |
| HRP20110919T1 (hr) | Nova upotreba alfuzosina u terapiji | |
| MX2010011401A (es) | Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica. | |
| ES2421605T3 (es) | Inhibidores de trastorno isquémico o enfermedades | |
| TR201901012T4 (tr) | Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı. | |
| ZA202006986B (en) | Dantrolene formulations and methods of their use |